MedTrace Logo

Iparomlimab and Tuvonralimab Injection (QL1706) Combined With DOS as Neoadjuvant Therapy for Locally Advanced Adenocarcinoma of the Stomach and Gastroesophageal Junction

NCT07776639 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 34

Last updated 2026-08-20

No results posted yet for this study

Summary

This is a single-center, prospective, exploratory clinical study. Eligible patients will be enrolled and receive iapalolimab combined with DOS regimen (docetaxel + oxaliplatin + tegafur-gimeracil-oteracil potassium). The study aims to further explore the efficacy and safety of iapalolimab plus DOS regimen for locally advanced gastric or gastroesophageal junction adenocarcinoma. A total of 34 patients with locally advanced gastric or gastroesophageal junction adenocarcinoma will be enrolled. Each treatment cycle lasts 21 days. After 3-4 cycles, patients who are assessed as operable by investigators will undergo surgical resection, and postoperative pathological results will be evaluated. The primary outcome measure is the pathological complete response rate. Investigators will determine subsequent treatment regimens based on patients' pathological findings and routine clinical practice at the study center. Radiological assessment of tumor response is recommended every 2 cycles.

Conditions

  • Gastroesophageal Junction Adenocarcinoma
  • Gastric Adenocarcinoma

Interventions

DRUG

Iparomlimab and Tuvonralimab Injection (QL1706)

5 mg/kg intravenous infusion on Day 1 every 3 weeks.

DRUG

S-1

40 mg/m² orally twice daily on Day 1-14 every 3 weeks.

DRUG

Oxaliplatin

100 mg/m² intravenous infusion on Day 1 every 3 weeks.

DRUG

Docetaxel

40 mg/m² intravenous infusion on Day 1 every 3 weeks.

Sponsors & Collaborators

  • Yongxu Jia

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-05-10
Primary Completion
2028-08-31
Completion
2028-11-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07776639 on ClinicalTrials.gov